Skip to content
TrialScanner

NCT05375903

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1CompletedURGNLead

Registry record

Lead sponsor
UroGen Pharma Ltd.
Conditions
Non-muscle Invasive Bladder Cancer; NMIBC; Carcinoma in Situ of Bladder; Bladder Cancer; Urothelial Carcinoma Bladder
Primary completion
Jan 9, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05375903 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.